Infusions of CSL112, a reconstituted plasma-derived apoA-I, at both low (2 g) and high (6 g) doses administered as 4 weekly infusions beginning within 7 days of acute MI were not associated with alterations in either liver or kidney function. This evidence concerns the gene APOA1 and myocardial infarction.